Drug details
Kisqali (ribociclib tablets)
type of Antineoplastics Aromatase Inhibitor, Antineoplastics CDK Inhibitors
Kisqali (ribociclib) is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
This drug may have the following side effects:
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- nausea,
- dark urine,
- vomiting,
- fever,
- shortness of breath,
- stomach pain,
- chest pain,
- cough
- fainting,
- sore throat,
- yellowing of the eyes or skin (jaundice),
- swollen lymph nodes,
- severe dizziness,
- chills, and
- fast, or irregular heartbeat,
The following drugs are related to Kisqali, either as a replacement or used together:
- Arimidex (anastrozole)
- Climara (estradiol transdermal)
- Climara Pro (estradiol, levonorgestrel transdermal)
- Delestrogen (estradiol valerate)
- Depo-Estradiol (estradiol cypionate injection)
- Elestrin (estradiol gel)
- Enhertu (fam-trastuzumab deruxtecan-nxki for injection)
- Halaven Injection (eribulin mesylate)
- Femring (estradiol acetate)
- EstroGel (estradiol gel)
- Estrasorb (estradiol topical emulsion)
- Vivelle-Dot (estradiol transdermal system)
- Menostar (estradiol transdermal system)
- Estring (estradiol vaginal ring)
- Vagifem (estradiol vaginal tablets)
- Menest (estrogens)
- Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection, for subcutaneous use)
- Nolvadex (tamoxifen citrate)
- Ontruzant (trastuzumab-dttb for injection)
- Perjeta (pertuzumab)
- Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf injection)
- Soltamox (tamoxifen citrate)
- Talzenna (talazoparib capsules)
- Trazimera (trastuzumab-qyyp for injection)